{"id":2521,"date":"2014-12-05T00:00:00","date_gmt":"2014-12-05T08:00:00","guid":{"rendered":"https:\/\/vermont.salk.edu\/news-release\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\/"},"modified":"2014-12-05T00:00:00","modified_gmt":"2014-12-05T08:00:00","slug":"salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman","status":"publish","type":"disclosure","link":"https:\/\/www.salk.edu\/de\/news-release\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\/","title":{"rendered":"Salk Institute Board of Trustees welcomes biotech entrepreneur Richard Heyman"},"content":{"rendered":"<p>\nLA JOLLA\u2013The Salk Institute is pleased to announce the election of Richard A. Heyman, PhD, to its Board of Trustees. Heyman currently serves as CEO of <a href=\"http:\/\/www.seragonpharm.com\/\" target=\"_blank\">Seragon Pharmaceuticals<\/a>, a San Diego-based biotech company that he co-founded in August 2013. Seragon develops selective estrogen receptor degraders (SERDs), which are being used for the treatment of breast cancer.\n<\/p>\n<div class=\"imageCaption\" style=\"width:200px;\"><img decoding=\"async\" style=\"border-bottom: 1px #006699 solid;\" alt=\"\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2014\/01\/2065.jpg\"><\/p>\n<p>Richard A. Heyman<\/p>\n<p>\nBild: Mit freundlicher Genehmigung des Salk Institute for Biological Studies\n<\/p>\n<\/div>\n<p>\n\u201cRich\u2019s record of leadership in the biotech industry and his successes as an entrepreneur will make him a valuable addition to our board,\u201d says Salk Board Chairman Irwin M. Jacobs. \u201cHe offers insight, experience and professional expertise that will further expand the Salk Institute\u2019s scientific impact.\u201d\n<\/p>\n<p>\nHeyman\u2019s affinity for the Salk Institute extends beyond his background in biotech. He once worked at the Salk Institute as a <a href=\"http:\/\/nih.gov\" target=\"_blank\">Nationale Gesundheitsinstitute<\/a> postdoctoral fellow and staff scientist. With Salk Professor <a href=\"https:\/\/www.salk.edu\/de\/faculty\/evans.html\/\">Ron Evans<\/a>, Heyman co-founded X-Ceptor Therapeutics, which was acquired by Exelixis in 2004.\n<\/p>\n<p>\nPrior to Seragon, Heyman was the CEO and co-founder of Aragon Pharmaceuticals, which developed novel therapeutics for the treatment of hormone dependent cancers, such as prostate and breast cancers, based on new insights into molecular mechanisms of resistance. Prior to X-Ceptor, he held various roles at Ligand Pharmaceuticals, including Vice President of Research, where he lead a project to develop Panretin\u00ae and Targretin\u00ae, retinoids approved by the FDA for the treatment of cancer. He is the author or inventor on more than 120 publications and patents.\n<\/p>\n<p>\nHeyman serves on the board of directors for BIOCOM, Organovo Inc. and Receptos Inc. He is a member of the therapeutic advisory board for aTyr Pharma, and serves on the executive committee of the UCSD Moores Cancer Center. He received a PhD in pharmacology from the University of Minnesota, and a BS in chemistry from the University of Connecticut.\n<\/p>\n<p>\n<strong>\u00dcber das Salk Institute for Biological Studies:<\/strong><br \/>\nThe Salk Institute for Biological Studies is one of the world&#8217;s preeminent basic research institutions, where internationally renowned faculty probe fundamental life science questions in a unique, collaborative and creative environment. Focused both on discovery and on mentoring future generations of researchers, Salk scientists make groundbreaking contributions to our understanding of cancer, aging, Alzheimer&#8217;s, diabetes and infectious diseases by studying neuroscience, genetics, cell and plant biology, and related disciplines.\n<\/p>\n<p>\nDie Leistungen der Fakult\u00e4t wurden mit zahlreichen Auszeichnungen gew\u00fcrdigt, darunter Nobelpreise und Mitgliedschaften in der National Academy of Sciences. Das 1960 vom Polio-Impfstoff-Pionier Dr. Jonas Salk gegr\u00fcndete Institut ist eine unabh\u00e4ngige gemeinn\u00fctzige Organisation und ein architektonisches Wahrzeichen.<\/p>","protected":false},"featured_media":0,"template":"","faculty":[],"disease-research":[144],"class_list":["post-2521","disclosure","type-disclosure","status-publish","hentry","disease-research-leadership"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Salk Institute Board of Trustees welcomes biotech entrepreneur Richard Heyman - Salk Institute for Biological Studies<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.salk.edu\/de\/news-release\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salk Institute Board of Trustees welcomes biotech entrepreneur Richard Heyman - Salk Institute for Biological Studies\" \/>\n<meta property=\"og:description\" content=\"LA JOLLA\u2013The Salk Institute is pleased to announce the election of Richard A. Heyman, PhD, to its Board of Trustees. Heyman currently serves as CEO of Seragon Pharmaceuticals, a San Diego-based biotech company that he co-founded in August 2013. Seragon develops selective estrogen receptor degraders (SERDs), which are being used for the treatment of breast cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.salk.edu\/de\/news-release\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\/\" \/>\n<meta property=\"og:site_name\" content=\"Salk Institute for Biological Studies\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk-institute-preview-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"628\" \/>\n\t<meta property=\"og:image:height\" content=\"329\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\\\/\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\\\/\",\"name\":\"Salk Institute Board of Trustees welcomes biotech entrepreneur Richard Heyman - Salk Institute for Biological Studies\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/2065.jpg\",\"datePublished\":\"2014-12-05T08:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\\\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/2065.jpg\",\"contentUrl\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/2065.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.salk.edu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salk Institute Board of Trustees welcomes biotech entrepreneur Richard Heyman\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"name\":\"Salk Institute for Biological Studies\",\"description\":\"The Power of Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.salk.edu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\",\"name\":\"Salk Institute for Biological Studies\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"contentUrl\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"width\":696,\"height\":696,\"caption\":\"Salk Institute for Biological Studies\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Salk Institute Board of Trustees welcomes biotech entrepreneur Richard Heyman - Salk Institute for Biological Studies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.salk.edu\/de\/news-release\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\/","og_locale":"de_DE","og_type":"article","og_title":"Salk Institute Board of Trustees welcomes biotech entrepreneur Richard Heyman - Salk Institute for Biological Studies","og_description":"LA JOLLA\u2013The Salk Institute is pleased to announce the election of Richard A. Heyman, PhD, to its Board of Trustees. Heyman currently serves as CEO of Seragon Pharmaceuticals, a San Diego-based biotech company that he co-founded in August 2013. Seragon develops selective estrogen receptor degraders (SERDs), which are being used for the treatment of breast cancer.","og_url":"https:\/\/www.salk.edu\/de\/news-release\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\/","og_site_name":"Salk Institute for Biological Studies","og_image":[{"width":628,"height":329,"url":"https:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk-institute-preview-image.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.salk.edu\/news-release\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\/","url":"https:\/\/www.salk.edu\/news-release\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\/","name":"Salk Institute Board of Trustees welcomes biotech entrepreneur Richard Heyman - Salk Institute for Biological Studies","isPartOf":{"@id":"https:\/\/www.salk.edu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.salk.edu\/news-release\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\/#primaryimage"},"image":{"@id":"https:\/\/www.salk.edu\/news-release\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\/#primaryimage"},"thumbnailUrl":"https:\/\/www.salk.edu\/wp-content\/uploads\/2014\/01\/2065.jpg","datePublished":"2014-12-05T08:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.salk.edu\/news-release\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.salk.edu\/news-release\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.salk.edu\/news-release\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\/#primaryimage","url":"https:\/\/www.salk.edu\/wp-content\/uploads\/2014\/01\/2065.jpg","contentUrl":"https:\/\/www.salk.edu\/wp-content\/uploads\/2014\/01\/2065.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.salk.edu\/news-release\/salk-institute-board-of-trustees-welcomes-biotech-entrepreneur-richard-heyman\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.salk.edu\/"},{"@type":"ListItem","position":2,"name":"Salk Institute Board of Trustees welcomes biotech entrepreneur Richard Heyman"}]},{"@type":"WebSite","@id":"https:\/\/www.salk.edu\/#website","url":"https:\/\/www.salk.edu\/","name":"Salk-Institut f\u00fcr biologische Studien","description":"Die Macht der Wissenschaft","publisher":{"@id":"https:\/\/www.salk.edu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.salk.edu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/www.salk.edu\/#organization","name":"Salk-Institut f\u00fcr biologische Studien","url":"https:\/\/www.salk.edu\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/","url":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","contentUrl":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","width":696,"height":696,"caption":"Salk Institute for Biological Studies"},"image":{"@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/"}}]}},"ACF":{"paper_url":"","journal_title":"","paper_author_list":"","paper_title":"","subhead":"","home_photo":"2065.jpg","listing_photo":"","line_2":"","line_1":"Salk Institute Board of Trustees welcomes biotech entrepreneur Richard Heyman"},"_links":{"self":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/disclosure\/2521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/disclosure"}],"about":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/types\/disclosure"}],"version-history":[{"count":0,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/disclosure\/2521\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/media?parent=2521"}],"wp:term":[{"taxonomy":"faculty","embeddable":true,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/faculty?post=2521"},{"taxonomy":"disease-research","embeddable":true,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/disease-research?post=2521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}